Datum: 18 augustus 2006
As described in the following article, Dr. De Meirleir reports that his research indicates Chronic Fatigue Syndrome patients can be differentiated from healthy people with 99 percent accuracy based on a test for the presence of “low molecular weight” RNase L in the blood. He says the weight of LMW RNase L molecules found in the blood of CFS patients is less than half that of normal RNase L molecules. (And this holds true for individuals with several other illnesses, including Fibromyalgia.) Increased symptom severity correlates directly with increased levels of LMW RNase L.
Additionally, though Dr. De Meirleir emphasizes that each patient’s profile is unique, he says his research indicates that CFS patients tend to fall into three groups with different test profiles and treatments. Based on the results of six tests, he reports he has been able to predict patients’ symptoms with 95 percent accuracy while the remaining 5 percent had overlap features.